Primary cutaneous Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma, not otherwise specified, in a nonimmunocompromised young man: A case report

Mo, Xiaoning; Zhou, Min-yan; Ye, Qiurong

doi:10.1111/cup.13602

Cited by 3 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic inflammation is a precursor of most tumours, and Epstein Barr virus infection is often implicated in primary cutaneous diffuse large B-cell lymphoma, which is concerned with chronic inflammatory stimulation [ 52 , 53 ]. Pro-inflammatory mediator not only participates in acute infectious diseases but is also involved in the evolution of sterile inflammation [ 54 ].…”

Section: Discussionmentioning

confidence: 99%

Primary cutaneous diffuse large B-cell lymphoma after total knee arthroplasty: a case study and a systematic review of its cutaneous manifestations and treatment options

Chen¹,

Si²,

Gao³

et al. 2022

pdia

View full text Add to dashboard Cite

Introduction: Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) after total knee arthroplasty (TKA) is rare. Aim: The literature that analyses the cutaneous manifestations of PCDLBCL and assesses the effect and the outcome of treatment is scarce. Material and methods: We described a case of PCDLBCL after TKA, whose cutaneous mass develops around surgical sites, mimicking a prosthetic joint infection. In addition, we conducted a systematic review of 29 reported cases with PCDLBCL. Primary endpoint for the review was main cutaneous manifestations of PCDLBCL. Secondary endpoint included treatment options of PCDLBCL and optimal therapeutic method. Results: We found that the main cutaneous manifestations include infiltrative cutaneous lesions such as macules, papules or nodules, some of them presented as ulcerations or formation of vesicles, subcutaneous nodules or both. The treatment options include excision, radiotherapy, chemotherapy, and even "watchful waiting" as spontaneous regression was noted in some cases. Systemic chemotherapy is the most frequent initial treatment approach chosen, of which rituximab is often combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy and patients who received systemic rituximab tend to have a better overall survival (OS) time than those who did not. Conclusions: PCDLBCL is a rare disease after TKA, however, an early recognition and distinguishing from infection is still needed. Patients with PCDLBCL may profit from rituximab-based chemotherapy, increasing the survival rate, despite the high relapse rate and limited OS time in some cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary cutaneous diffuse large B-cell lymphoma after total knee arthroplasty: a case study and a systematic review of its cutaneous manifestations and treatment options

Chen¹,

Si²,

Gao³

et al. 2022

pdia

View full text Add to dashboard Cite

show abstract

“…The key feature is necrosis and ulceration of the skin tumors in the absence of therapy. In addition, albeit rare to date, cases suggestive of this diagnosis have been observed in patients with untreated solid tumors (such as melanoma, breast cancer, and Kaposi sarcoma) [7,[27][28][29][30][31][32][33][34][35][36][37][38][39].…”

Section: Spontaneous (Idiopathic) Cutaneous Tumor Lysis Syndromementioning

confidence: 99%

“…There is subsequent necrosis and ulcer formation as the clinical presentation of spontaneous (idiopathic) cutaneous tumor lysis syndrome. However, it remains unclear if some of these cases were accompanied by rapid tumor death, a key feature of cutaneous tumor lysis syndrome [7,[27][28][29][30][31][32][33][34][35][36][37][38][39]. Solid tumors: In addition to patients with Kaposi sarcoma, characteristics possibly compatible with solid tumor-associated spontaneous (idiopathic) cutaneous tumor lysis syndrome have also been reported in patients with other solid tumors (Table 4) [7,[35][36][37][38][39].…”

Section: Spontaneous (Idiopathic) Cutaneous Tumor Lysis Syndromementioning

confidence: 99%

“…[27][28][29][30]. The B-cell neoplasms of patients possibly presenting with characteristics of spontaneous (idiopathic) cutaneous tumor lysis syndrome include cutaneous B-cell lymphoma, intravascular B-cell lymphoma, primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified, and cutaneous lymphomatoid granulomatosis (Table 3)[31][32][33][34]. of 50 patients with primary and recurrent mycosis fungoides, 14 had either erythroderma and/or ulcerated lesions, on initial presentation; some of the patients with ulcerated lesions might be…”

mentioning

confidence: 99%

See 1 more Smart Citation

Tumor Lysis Syndrome: Introduction of a Cutaneous Variant and a New Classification System

Cohen¹,

Prieto

Kurzrock

2021

Cureus

View full text Add to dashboard Cite

Tumor lysis syndrome, an oncological emergency, is characterized by laboratory parameters such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, as well as renal injury with an elevated creatinine. Tumor lysis syndrome is seen in patients with aggressive malignancies and high tumor burden. More frequently, it occurs in individuals with hematologic malignancies such as high-grade lymphomas (such as Burkitt lymphoma) and leukemia (such as acute lymphocytic leukemia). It also, albeit less commonly, can be seen in patients with widespread solid tumors that are rapidly proliferating and are markedly sensitivity to antineoplastic therapy. Tumor lysis syndrome is usually preceded by cancer-directed therapy; however, the syndrome can present spontaneously prior to the individual receiving malignancydirected treatment. We reported a man with metastatic salivary duct carcinoma who had cutaneous metastases that presented as carcinoma hemorrhagiectoides. Microscopic examination demonstrated that the metastatic tumor cells had infiltrated and replaced the entire dermis. After the patient received his first dose of antineoplastic therapy, he had an excellent response and the cutaneous metastases developed into ulcers; we hypothesize that most of the dermis, which had been replaced by tumor cells, disappeared as a result of the therapeutic response, and the overlying epidermis became necrotic and shed, leaving an ulcer. His dramatic response to treatment prompted us to propose a new classification of tumor lysis syndrome, which should include the systemic form of the condition as well as the new variant: cutaneous tumor lysis syndrome. We anticipate that, with improvement in targeted therapies, there may be an increase in therapyassociated cutaneous tumor lysis syndrome.

show abstract

Epstein–Barr Virus‐Associated Lymphoproliferative Disorders/Lymphoma with Skin Manifestations as the Primary Symptom: A Systematic Review

Li,

Feng,

Zeng

2024

Dermatologic Therapy

View full text Add to dashboard Cite

Background. Epstein–Barr virus (EBV) associated skin lesions have been mentioned in case report studies under multiple kinds of lymphoproliferative disorders/lymphoma diagnoses. However, due to the rarity and scattered reporting of cases, it is still unclear whether the related skin symptoms and their pathological findings can guide the clinical diagnosis and treatment of EBV‐associated lymphoproliferative disease/lymphoma. Methods. In this review, we summarized the skin symptoms and clinicopathological features mentioned by previously reported cases of EBV‐associated lymphoproliferative disorders/lymphoma to assist future clinical diagnosis. The inclusion criteria were based on the population, intervention, comparator, outcomes, and study designs. An electronic search was conducted by September 2023, and the following databases were used: PubMed, EMBASE, Cochrane Library, and Web of Science. Search keywords included “Epstein-Barr Virus Infections,” “Herpesvirus 4, Human,” “Lymphoma,” “Lymphoproliferative Disorders,” and “skin.” Results. The primary outcome was the clinical skin features and pathological findings of EBV‐associated lymphoproliferative disease/lymphoma patients. Although it seems unrealistic to differentiate between patients with EBV‐related lymphoproliferative disorders/lymphomas with different diagnoses on the basis of cutaneous symptoms and pathological findings alone, based on the evidence summarized in previous case reports, the clinical importance of EBV detection and identification in the differential diagnosis of lymphomas and lymphoproliferative disorders should be recognized. Conclusion. Given the homogeneity of risk factors associated with disease progression found in EBV‐associated lymphoproliferative disease/lymphoma patients during the review, future studies can focus on summarizing skin symptoms and pathological outcomes based on possible risk factors for further deterioration in these patients.

show abstract

Primary cutaneous Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma, not otherwise specified, in a nonimmunocompromised young man: A case report

Cited by 3 publications

References 6 publications

Primary cutaneous diffuse large B-cell lymphoma after total knee arthroplasty: a case study and a systematic review of its cutaneous manifestations and treatment options

Primary cutaneous diffuse large B-cell lymphoma after total knee arthroplasty: a case study and a systematic review of its cutaneous manifestations and treatment options

Tumor Lysis Syndrome: Introduction of a Cutaneous Variant and a New Classification System

Epstein–Barr Virus‐Associated Lymphoproliferative Disorders/Lymphoma with Skin Manifestations as the Primary Symptom: A Systematic Review

Contact Info

Product

Resources

About